{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:04Z","timestamp":1792172464762,"version":"4.4.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamaneurol.2020.0851","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T11:01:07Z","timestamp":1588590067000},"page":"974","source":"Crossref","is-referenced-by-count":119,"title":["Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis"],"prefix":"10.1001","volume":"77","author":[{"given":"Susanna","family":"Brauner","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eriksson-Dufva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Albert","family":"Hietala","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayomand","family":"Press","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi200019r1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis.","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"noi200019r2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/joim.2015.277.issue-5","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study.","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med"},{"key":"noi200019r3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"issue":"10","key":"noi200019r4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies.","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi200019r5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy.","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"noi200019r6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis.","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"4","key":"noi200019r7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary.","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"noi200019r8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"23","key":"noi200019r9","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"noi200019r10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics.","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"noi200019r11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"issue":"3","key":"noi200019r12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"issue":"10","key":"noi200019r13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review.","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"24","key":"noi200019r14","doi-asserted-by":"publisher","first-page":"e2182","DOI":"10.1212\/WNL.0000000000005692","article-title":"B-cell targeted treatment in myasthenia gravis (BeatMG): a phase 2 trial of rituximab in myasthenia gravis: topline results.","volume":"90","author":"Nowak","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"noi200019r15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"issue":"20","key":"noi200019r16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy.","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"noi200019r17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis.","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi200019r18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1352458511418631","article-title":"Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.","volume":"18","author":"Nielsen","year":"2012","journal-title":"Mult Scler"},{"issue":"9","key":"noi200019r19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies.","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult Scler"},{"key":"noi200019r20","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis.","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"noi200019r21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis.","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"noi200019r22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2011.04.005","article-title":"Treatment of multiple sclerosis with anti-CD20 antibodies.","volume":"142","author":"Barun","year":"2012","journal-title":"Clin Immunol"},{"issue":"10","key":"noi200019r23","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years.","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"issue":"9","key":"noi200019r24","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"noi200019r25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells.","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"noi200019r26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1084\/jem.192.6.813","article-title":"Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival.","volume":"192","author":"Sze","year":"2000","journal-title":"J Exp Med"},{"issue":"2","key":"noi200019r27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood-2007-08-108118","article-title":"Increased survival is a selective feature of human circulating antigen-induced plasma cells synthesizing high-affinity antibodies.","volume":"111","author":"Gonz\u00e1lez-Garc\u00eda","year":"2008","journal-title":"Blood"},{"issue":"1","key":"noi200019r28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1084\/jem.194.1.45","article-title":"A coordinated change in chemokine responsiveness guides plasma cell movements.","volume":"194","author":"Hargreaves","year":"2001","journal-title":"J Exp Med"},{"issue":"1-2","key":"noi200019r29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jneuroim.2013.09.017","article-title":"Rituximab ameliorates anti-N-methyl-d-aspartate receptor encephalitis by removal of short-lived plasmablasts.","volume":"265","author":"Hachiya","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"47","key":"noi200019r30","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"noi200019r31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis.","volume":"19","author":"Li","year":"2018","journal-title":"Nat Immunol"},{"issue":"1","key":"noi200019r32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis.","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"issue":"1","key":"noi200019r33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.2018.1412.issue-1","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"noi200019r34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up.","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"noi200019r35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody\u2013positive myasthenia gravis.","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi200019r36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.v61.3","article-title":"Low-dose rituximab every 6?months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.","volume":"61","author":"Lu","year":"2020","journal-title":"Muscle Nerve"},{"key":"noi200019r37","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies.","author":"Luna","journal-title":"JAMA Neurol"},{"key":"noi200019r38","unstructured":"A study evaluating the safety and efficacy of rituximab in patients with myasthenia gravis (Rinomax). ClinicalTrials.gov Identifier: NCT02950155. Updated March 13, 2020. Accessed March 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02950155"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2765474\/jamaneurology_brauner_2020_oi_200019_1596744472.00726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T11:21:02Z","timestamp":1597058462000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2765474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}